Loading…
Verrica Pharmaceuticals Inc. is projected to decline to $5.12 by 2027, a -2% move from its current price of $5.22. VRCA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $5.04 | $5.22 | $5.40 | 0.00% |
| Aug 6 | $4.97 | $5.22 | $5.48 | 0.00% |
| Aug 7 | $4.92 | $5.22 | $5.54 | +0.01% |
| Aug 8 | $4.87 | $5.22 | $5.60 | +0.01% |
| Aug 9 | $4.83 | $5.22 | $5.64 | +0.01% |
| Aug 10 | $4.80 | $5.22 | $5.68 | +0.01% |
| Aug 11 | $4.76 | $5.22 | $5.72 | +0.01% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.76 | $5.22 | $5.72 | +0.01% |
| Week 2 | $4.59 | $5.22 | $5.95 | +0.03% |
| Week 3 | $4.45 | $5.22 | $6.12 | +0.04% |
| Week 4 | $4.35 | $5.22 | $6.28 | +0.05% |
| Week 5 | $4.25 | $5.22 | $6.41 | +0.07% |
| Week 6 | $4.17 | $5.22 | $6.54 | +0.08% |
| Week 7 | $4.10 | $5.22 | $6.66 | +0.09% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Verrica Pharmaceuticals Inc. is a healthcare company focused on dermatology therapeutics. It develops and commercializes medications for the treatment of dermatologic diseases in the United States.
The company offers YCANTH (VP-102), a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications.
Verrica has collaboration and license agreements with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan, and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. The company was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
VRCA is currently trading at $5.40 with a market capitalization of $92.77M and a rank of 4042. The current price sits near a framework of short- and longer-term resistance and support levels. The near-term forecast shows a mixed path, with a 2026 average price around $5.40 and a range from $4.38 to $6.82, and sentiment labeled Neutral.
The 30-day technical picture places the stock in a Bearish context, with a 30-day trading range from $4.34 to $6.72 and a support level at $5.35 and a resistance at $6.84. The stock’s volatility is relatively high, with annualized volatility around 60%.
Looking further out, the multi-year forecast shows a path from around mid-$5s in the near term to higher levels later in the decade and into the 2040s/2050s. The Avg prices rise over time, with notable bullish readings starting in 2032 and continuing through 2050, where the Avg is projected to reach $16.28 and the max around $32.50, accompanied by sizable ROI figures.
A major floor 25.8% below — a decisive break under it would weaken the trend.
The nearest floor, 3.8% below — buyers have tended to step in here.
The nearest ceiling, 31.0% above — a clean break opens room to run.
A major ceiling 61.5% above — clearing it would confirm fresh momentum.
Key VRCA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of VRCA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $5.28 | Sell | $5.27 | Sell |
| MA 10 | $5.35 | Sell | $5.38 | Sell |
| MA 20 | $5.69 | Sell | $5.57 | Sell |
| MA 50 | $5.86 | Sell | $5.84 | Sell |
| MA 100 | $5.99 | Sell | $5.99 | Sell |
| MA 200 | $6.09 | Sell | $6.54 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 40.98 | Neutral |
| Stoch RSI (14) | 51.15 | Neutral |
| CCI (20) | -85.52 | Neutral |
| Williams %R (14) | -78.02 | Info |
| MACD (12,26,9) | -0.04 | Sell |
| ROC (12) | -7.77 | Sell |
| Bollinger %B (20,2) | 0.23 | Neutral |
| Stochastic %K (14) | 21.98 | Neutral |
| TRIX (15) | -0.44 | Sell |
| Awesome (5,34) | -0.53 | Sell |
| Ultimate (7,14,28) | 35.19 | Neutral |
| Momentum (10) | -0.37 | Sell |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 5.21 | Buy |
| ADX (14) | 14.56 | Neutral |
| ATR (14) | 0.19 | Info |
The near-term technical picture is Bearish in sentiment, with an RSI of 40 indicating modest momentum weakness. The stock trades below the longer-term moving averages, with SMA50 at $5.98 and SMA200 at $6.07, suggesting limited upside pressure in the immediate horizon.
A threshold of support is noted at $5.35 and resistance at $6.84, framing a potential trading range near the current price. The 30-day price window runs from $4.34 to $6.72, signaling a relatively tight near-term range amid elevated volatility (annualized volatility around 60%).
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $4.38 | $5.22 | $6.66 | 0% | Neutral | |
| $3.98 | $5.12 | $7.02 | -2% | Neutral | |
| $4.31 | $5.75 | $8.24 | +10% | Neutral | |
| $3.86 | $5.30 | $7.89 | +2% | Neutral | |
| $3.87 | $5.47 | $8.38 | +5% | Neutral | |
| $4.62 | $6.70 | $10.53 | +28% | Bullish | |
| $5.11 | $7.59 | $12.20 | +45% | Bullish | |
| $5.59 | $8.47 | $13.91 | +62% | Bullish | |
| $5.40 | $8.36 | $13.99 | +60% | Bullish | |
| $5.01 | $7.92 | $13.49 | +52% | Bullish | |
| $7.27 | $12.61 | $23.10 | +142% | Bullish | |
| $8.90 | $18.24 | $37.09 | +249% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $4.38 | $5.22 | $6.36 | +0.00% |
| September 2026 | $4.31 | $5.14 | $6.32 | -1.60% |
| October 2026 | $4.35 | $5.23 | $6.52 | +1.80% |
| November 2026 | $4.43 | $5.36 | $6.76 | +2.58% |
| December 2026 | $4.29 | $5.23 | $6.66 | -2.50% |
Click any year to see its month-by-month VRCA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The VRCA price prediction for 2026 points to an average of $5.22 (low $4.38, high $6.66) — a potential gain of 0% on today's $5.22. A consolidation phase looks the most probable path here.
In 2027, VRCA is projected to trade between $3.98 and $7.02, averaging $5.12 — a potential decline of -2% from today's $5.22. That is -2% versus the projected 2026 average. Price action looks broadly range-bound.
Verrica Pharmaceuticals Inc.'s 2028 outlook centres on $5.75, within a $4.31 to $8.24 range. That is up +12% on the projected 2027 average. That marks a +10% change versus current levels. A consolidation phase looks the most probable path here.
By 2029, VRCA could reach as high as $7.89, with a base case around $5.30 and support toward $3.86 — roughly +2% from $5.22. Price action looks broadly range-bound.
Expect VRCA to range from $3.87 to $8.38 through 2030. The $5.47 average target implies a +5% move from current prices. That is up +3% on the projected 2029 average. A consolidation phase looks the most probable path here.
The VRCA price prediction for 2031 points to an average of $6.70 (low $4.62, high $10.53) — a potential gain of +28% on today's $5.22. Momentum favours further upside here.
In 2032, VRCA is projected to trade between $5.11 and $12.20, averaging $7.59 — a potential gain of +45% from today's $5.22. That is up +13% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Verrica Pharmaceuticals Inc.'s 2033 outlook centres on $8.47, within a $5.59 to $13.91 range. That is up +12% on the projected 2032 average. That marks a +62% change versus current levels. Momentum favours further upside here.
By 2034, VRCA could reach as high as $13.99, with a base case around $8.36 and support toward $5.40 — roughly +60% from $5.22. Buyers look set to stay in control over this stretch.
Expect VRCA to range from $5.01 to $13.49 through 2035. The $7.92 average target implies a +52% move from current prices. That is -5% versus the projected 2034 average. Momentum favours further upside here.
The VRCA price prediction for 2040 points to an average of $12.61 (low $7.27, high $23.10) — a potential gain of +142% on today's $5.22. Buyers look set to stay in control over this stretch.
In 2050, VRCA is projected to trade between $8.90 and $37.09, averaging $18.24 — a potential gain of +249% from today's $5.22. That is up +45% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in VRCA today (≈ 191.570881 VRCA) could be worth
$3,493.83
+$2,493.83 (+249%) by 2050 · US Dollar
Based on the average projected VRCA price of $18.24 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in VRCAwould be worth at today's price.
$1,000 invested in VRCA on Jul 31, 2025 (≈ 177.61989 VRCA) would be worth
$927.18
-$72.82 (-7.3%) today · 0.93× · US Dollar
Based on a VRCA entry price of $5.63 vs. today's $5.22.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $5.02 | $1,039.84 | +4.0% |
| 1 month ago | $5.94 | $878.79 | -12.1% |
| 3 months ago | $6.27 | $832.54 | -16.7% |
| 6 months ago | $7.45 | $700.67 | -29.9% |
| 1 year ago | $5.63 | $927.18 | -7.3% |
| All time (5.0y) ago | $111 | $47.03 | -95.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our VRCA forecast.
Our base-case forecast reaches $10.00 around 2040.
Implied market cap at $10.00: $171.79M
These are estimates, not guarantees. The year-by-year forecast shows a gradual rise in average price from the mid-$5s in the near term to substantially higher levels over the longer term, with a shift to bullish sentiment beginning in 2032 and continuing through 2050.
Key milestones include 2026 avg $5.40 with ROI 0 and Neutral sentiment, then 2030 avg $5.35 with ROI -0.9% and Neutral sentiment, followed by 2031 avg $6.36 with ROI 17.7% Neutral, and 2032 avg $7.12 with ROI 31.9% Bullish. The 2033–2035 period stays firmly Bullish, with 2033 avg $8.02 (ROI 48.6%), 2034 avg $7.90 (ROI 46.2%), and 2035 avg $7.42 (ROI 37.4%).
Beyond the mid-2030s, the forecast accelerates: 2040 avg $11.47 (ROI 112.5%), and 2050 avg $16.28 (ROI 201.4%). These are projections and reflect a possible upside path, but carry inherent uncertainty and variability across years.
Tap a question to reveal the answer.
2030 min $3.82, avg $5.35, max $8.12; ROI -0.9%; sentiment Neutral.
Forecasts show Neutral in 2026–2031 and Bullish from 2032 onward, with several years of positive ROI (e.g., 2032 ROI 31.9%, 2033 ROI 48.6%, 2040 ROI 112.5%, 2050 ROI 201.4%). These are estimates, not guarantees.
Yes. Max prices by year include 2033 $13.01, 2034 $13.04, 2040 $20.69, and 2050 $32.50, indicating potential to exceed $10 in multiple years.
Current price is $5.40 and market cap is $92.77M.
In 2040, the Avg is projected to be $11.47 with ROI 112.5%. By 2050, the Avg is projected to be $16.28 with ROI 201.4%.
Verrica Pharmaceuticals Inc. Community Discussion
0Share your Verrica Pharmaceuticals Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.